Eleanor McCabe, Edward A. Medina, Margarita Peterson, Tomasz Drewa, Karol Polom, Katarzyna Pietkun, Maciej Nowacki, Tomasz Kloskowski, Delia Cortes Guiral, Franco Roviello, Marta Pokrywczyńska, Wojciech Zegarski, Samy L. Habib, and Barbara Zegarska
// Maciej Nowacki 1 , Margarita Peterson 2 , Tomasz Kloskowski 3 , Eleanor McCabe 2 , Delia Cortes Guiral 4 , Karol Polom 5, 6 , Katarzyna Pietkun 7 , Barbara Zegarska 7 , Marta Pokrywczynska 3 , Tomasz Drewa 3 , Franco Roviello 7 , Edward A. Medina 8 , Samy L. Habib 9, 10 and Wojciech Zegarski 1 1 Chair of Department of Surgical Oncology, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Oncology Centre of Franciszek Łukaszczyk Memorial Hospital, Bydgoszcz, Poland 2 Department of Plastic and Reconstructive Surgery, Wake Forest School of Medicine, Winston-Salem, NC, USA 3 Chair of Urology, Department of Regenerative Medicine, Ludwik Rydygier’s Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Torun, Poland 4 Department of General Surgery (Peritoneal Surface Surgical Oncology), Fundacion Jimenez Diaz Hospital, Madrid, Spain 5 General Surgery and Surgical Oncology Department, University of Siena, Siena, Italy 6 Department of Surgical Oncology, Medical University of Gdansk, Gdansk, Poland 7 Chair of Cosmetology and Aesthetic Dermatology, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun. Bydgoszcz, Poland 8 Department of Pathology, University of Texas Health, San Antonio, TX, USA 9 Department of Cell Systems and Anatomy, University of Texas Health Geriatric Research Education, San Antonio, TX, USA 10 South Texas Veterans Health Care System, San Antonio, TX, USA Correspondence to: Maciej Nowacki, email: maciej.s.nowacki@gmail.com Samy L. Habib, email: habib@uthscsa.edu Keywords: CRS + HIPEC, HIPEC, PIPAC, peritoneal carcinomatosis, nanomedicine Received: April 21, 2017 Accepted: August 15, 2017 Published: August 31, 2017 ABSTRACT The treatment of peritoneal surface malignances has changed considerably over the last thirty years. Unfortunately, the palliative is the only current treatment for peritoneal carcinomatosis (PC). Two primary intraperitoneal chemotherapeutic methods are used. The first is combination of cytoreductive surgery (CRS) and Hyperthermic IntraPEritoneal Chemotherapy (HIPEC), which has become the gold standard for many cases of PC. The second is Pressurized IntraPeritoneal Aerosol Chemotheprapy (PIPAC), which is promising direction to minimally invasive as safedrug delivery. These methods were improved through multicenter studies and clinical trials that yield important insights and solutions. Major method development has been made through nanomedicine, specifically nanoparticles. Here, we are presenting the latest advances of nanoparticles and their application to precision diagnostics and improved treatment strategies for PC. These advances will likely develop both HIPEC and PIPAC methods that used for in vitro and in vivo studies. Several benefits of using nanoparticles will be discussed including: 1) Nanoparticles as drug delivery systems; 2) Nanoparticles and Near Infrred (NIR) Irradiation; 3) use of nanoparticles in perioperative diagnostic and individualized treatment planning; 4) use of nanoparticles as anticancer dressing’s, hydrogels and as active beeds for optimal reccurence prevention; and 5) finally the curent in vitro and in vivo studies and clinical trials of nanoparticles. The current review highlighted use of nanoparticles as novel tools in improving drug delivery to be effective for treatment patients with peritoneal carcinomatosis.